Ongoing Investigations of Nelabarine and Daratumumab May Improve Outcomes in T-ALL

Investigating the addition of novel agents to cytotoxic chemotherapy may help prevent relapse in patients with T-cell acute lymphoblastic leukemia by bolstering the efficacy of these standard frontline therapies.

Related Keywords

New York ,United States ,Rochester ,University Of Rochester Medical Center ,Philadelphia ,Pennsylvania ,Texas ,Houston ,Kristen Odwyer ,Venetoclax Venclexta ,Department Of Medicine ,Children Oncology Group ,Meeting Of The Society Hematologic Oncology ,Kristeno Dwyer ,Rochester Medical Center School ,Oncology Group ,Annual Meeting ,Hematologic Oncology ,Society Of Hematologic Oncology Annual Meeting Soho ,News ,Conference ,Myelodysplastic Syndrome ,Non Hodgkin Lymphoma ,Nce Hematologic Oncology ,Nelabarine ,Daratumumab ,